The company reaffirmed its financial guidance for the fiscal year 2023. The company expects revenue for the fiscal year 2023 to grow approximately 16% to 18% compared to prior year results, ranging from $475 million to $485 million. The company expects gross margin for the fiscal year 2023 to range from 69% to 70%. Adjusted EBITDA margin for the full year 2023 is expected to range from approximately negative 0.5% to 0.5% of revenues.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on IRTC:
- BTIG finds medical technology stocks with exposure with SVB
- iRhythm provides update on investments with SVB Financial
- iRhythm announces results of multiple new studies at ACC.23/WCC
- Large Real-World Evidence Analysis Demonstrates that Zio® XT Is Associated With the Highest Diagnostic Yield, Lowest Retesting Rates, and Fastest Time to Clinical Diagnosis Compared to Other Ambulatory ECG Monitors
- Four New Studies Featuring Zio® by iRhythm to be Presented at ACC.23/WCC